Status:
COMPLETED
Non Interventional Study With Primary Open Angle Glaucoma and/or Ocular Hypertension Patients Treated With Xalacom® After Failure of Previous Antiglaucoma Therapy.
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Glaucoma, Open-angle
Eligibility:
All Genders
18-99 years
Brief Summary
This study is designed to evaluate the safety and tolerability of Xalacom in patients with primary glaucoma
Detailed Description
according to physicians decision, patients who met inclusion and exclusion criteria and sign the ICD
Eligibility Criteria
Inclusion
- primary open angle glaucoma
- ocular hypertension
- age \>18 years
Exclusion
- bradycardia
- obstructive pulmonary disease
- hypersensitivity to the drug
Key Trial Info
Start Date :
October 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2009
Estimated Enrollment :
457 Patients enrolled
Trial Details
Trial ID
NCT00801437
Start Date
October 1 2008
End Date
June 1 2009
Last Update
February 18 2021
Active Locations (39)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Banovce N. Bebravou, Slovakia, 957 01
2
Pfizer Investigational Site
Banská Bystrica, Slovakia, 975 17
3
Pfizer Investigational Site
Bojnice, Slovakia, 972 01
4
Pfizer Investigational Site
Bratislava, Slovakia, 811 05